Literature DB >> 16562585

Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury.

D Ismail1, M A O'Connell, M R Zacharin.   

Abstract

UNLABELLED: Unrelenting weight gain, morbid obesity and disturbance of the sleep-wake cycle are well-recognized sequelae of hypothalamic injury. These health problems and their risk of significant associated co-morbidity drive the search for potential treatment modalities.
OBJECTIVE: To report effects on weight change and wakefulness in a cohort of 12 patients with structural hypothalamic lesions treated with low-dose dexamphetamine.
METHOD: Retrospective review of case notes.
RESULTS: Twelve patients received dexamphetamine 5 mg twice daily (median duration 13 months in males, 15 months in females). Ten of 12 patients experienced either stabilisation of weight or weight loss on treatment (median loss -0.7 SDS in males, -0.44 SDS in females). Eleven patients reported improvement in daytime wakefulness and/or concentration and exercise tolerance.
CONCLUSION: Low-dose dexamphetamine therapy has a positive impact on inexorable weight gain and daytime somnolence following hypothalamic injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16562585     DOI: 10.1515/jpem.2006.19.2.129

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  22 in total

1.  Hypothalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery.

Authors:  Gabrielle Page-Wilson; Sharon L Wardlaw; Alexander G Khandji; Judith Korner
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

2.  A novel rodent model that mimics the metabolic sequelae of obese craniopharyngioma patients.

Authors:  Christian L Roth; James E Blevins; Melissa Ralston; Clinton Elfers; Kayoko Ogimoto; Karl J Kaiyala; Gregory J Morton
Journal:  Pediatr Res       Date:  2011-03       Impact factor: 3.756

3.  Polysomnographic findings in craniopharyngioma patients.

Authors:  Line Pickering; Marianne Klose; Ulla Feldt-Rasmussen; Poul Jennum
Journal:  Sleep Breath       Date:  2017-09-27       Impact factor: 2.816

4.  Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series.

Authors:  Christian Denzer; Friederike Denzer; Belinda S Lennerz; Heike Vollbach; Robert H Lustig; Martin Wabitsch
Journal:  Obes Facts       Date:  2019-03-07       Impact factor: 3.942

Review 5.  Hypothalamic syndrome.

Authors:  Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen
Journal:  Nat Rev Dis Primers       Date:  2022-04-21       Impact factor: 52.329

Review 6.  Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans.

Authors:  Michelle Lee; Judith Korner
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 7.  Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls.

Authors:  C S Gautam; Jatin Sharma; Mandeep Singla; Ilmjot Kaur Tiwana; Harmanjit Singh
Journal:  touchREV Endocrinol       Date:  2021-04-28

8.  Long term sequelae of pediatric craniopharyngioma - literature review and 20 years of experience.

Authors:  Michal Cohen; Sharon Guger; Jill Hamilton
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-28       Impact factor: 5.555

9.  European guidelines on managing adverse effects of medication for ADHD.

Authors:  J Graham; T Banaschewski; J Buitelaar; D Coghill; M Danckaerts; R W Dittmann; M Döpfner; R Hamilton; C Hollis; M Holtmann; M Hulpke-Wette; M Lecendreux; E Rosenthal; A Rothenberger; P Santosh; J Sergeant; E Simonoff; E Sonuga-Barke; I C K Wong; A Zuddas; H-C Steinhausen; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-11-03       Impact factor: 4.785

10.  MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.

Authors:  Francisco A Perez; Clinton Elfers; Jack A Yanovski; Ashley H Shoemaker; M Jennifer Abuzzahab; Christian L Roth
Journal:  Diabetes Obes Metab       Date:  2021-03-29       Impact factor: 6.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.